Table 2.
Results from the biochemical assay after acute 1MeTIQ treatment
| Treatment | n | DA | DOPAC | 3-MT | HVA |
|---|---|---|---|---|---|
| FCX | |||||
| Control | 5 | 510 ± 29 | 159 ± 7 | 14 ± 1 | 155 ± 14 |
| MK-801 | 5 | 213 ± 36*** | 158 ± 10 | 17 ± 2 | 121 ± 16 |
| 1MeTIQ | 8 | 458 ± 39 | 96 ± 6 | 27 ± 5 | 152 ± 7 |
| Olanzapine | 10 | 319 ± 26** | 326 ± 14*** | 30 ± 11 | 272 ± 20*** |
| 1MeTIQ + MK-801 | 5 | 490 ± 46### | 92 ± 8*# | 24 ± 4 | 127 ± 6 |
| Olanzapine + MK-801 | 9 | 543 ± 37### | 370 ± 36***### | 19 ± 2 | 245 ± 23**### |
| F |
F(5/36) = 11.31 p < 0.001 |
F(5/38) = 37.92 p < 0.001 |
F(5/39) = 0.97 p = 0.45 |
F(5/39) = 12.72 p < 0.001 |
|
| HIP | |||||
| Control | 5 | 25 ± 1 | 11 ± 1 | 15 ± 2 | 17 ± 2 |
| MK-801 | 6 | 23 ± 3 | 17 ± 1* | 13 ± 1 | 21 ± 3 |
| 1MeTIQ | 10 | 34 ± 2* | 12 ± 1 | 20 ± 3 | 26 ± 3 |
| Olanzapine | 9 | 31 ± 2 | 26 ± 2*** | 22 ± 3* | 26 ± 3 |
| 1MeTIQ + MK-801 | 6 | 29 ± 2 | 12 ± 1+ | 10 ± 1 | 19 ± 3 |
| Olanzapine + MK-801 | 10 | 22 ± 2 | 17 ± 2* | 11 ± 1 | 26 ± 3 |
| F |
F(5/40) = 4.38 p < 0.01 |
F(5/39) = 15.42 p < 0.001 |
F(5/38) = 4.36 p < 0.01 |
F(5/38) = 1.51 p = 0.21 |
|
DA and its metabolites were measured in the Fcx and hippocampus using HPLC. The data were analyzed using one-way ANOVA and a post hoc Duncan’s MRT. The results are shown as the means ± SEM. N = 8–10 rats per group
*p < 0.05; **p < 0.01; ***p < 0.001 indicate significant changes compared to the control; #p < 0.05; ##p < 0.01; ###p < 0.001 indicate significant changes compared to the model (MK-801) group